Vaxcyte Inc
PCVX
NASDAQ
Biotechnology
$58.07
USD
-0.79 (-1.34%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $8.78B
Volume 656.6K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-1.06B
TTM
-94.4%
YoY
Operating Cash Flow
$-881.23M
TTM
-91.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 32.0 | 32.4 | 32.2 | 33.1 | 34.9 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 226.2 | 242.4 | 274.3 | 345.9 | 302.8 |
Operating Income | -226.2 | -242.4 | -274.3 | -345.9 | -302.8 |
EBITDA | -223.3 | -239.3 | -258.3 | -342.9 | -299.8 |
Other Income / Expense | 28.6 | 0.3 | 1.3 | -1.4 | -7.3 |
Total Other Income / Expense | 59.6 | 29.6 | 27.8 | 25.2 | 18.5 |
Income Before Income Taxes | -166.6 | -212.8 | -246.5 | -320.6 | -284.3 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -166.6 | -212.8 | -246.5 | -320.6 | -284.3 |
Consolidated Net Income / Loss | -166.6 | -212.8 | -246.5 | -320.6 | -284.3 |
Net Income Attributable to Common Shareholders | -166.6 | -212.8 | -246.5 | -320.6 | -284.3 |
Basic EPS | -$1.22 | -$1.56 | -$1.81 | -$2.30 | -$1.97 |
Diluted EPS | -$1.22 | -$1.56 | -$1.81 | -$2.30 | -$1.97 |
Basic Shares Outstanding | 136.0M | 136.2M | 136.4M | 139.5M | 144.5M |
Diluted Shares Outstanding | 136.0M | 136.2M | 136.4M | 139.5M | 144.5M |